Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis
Date
2016-11-24
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Abstract
Over the last 10 years, interest in pediatric tuberculosis (TB) has increased dramatically, together with increased
funding and research. We have a better understanding of the burden of childhood TB as well as a better idea of
how to diagnose it. Our appreciation of pathophysiology is improved and with it investigators are beginning to
consider pediatric TB as a heterogeneous entity, with different types and severity of disease being treated in
different ways. There have been advances in how to treat both TB infection and TB disease caused by both
drug-susceptible as well as drug-resistant organisms. Two completely novel drugs, bedaquiline and delamanid,
have been developed, in addition to the use of older drugs that have been re-purposed. New regimens are
being evaluated that have the potential to shorten treatment. Many of these drugs and regimens have first
been investigated in adults with children an afterthought, but increasingly children are being considered at the
outset and, in some instances studies are only conducted in children where pediatric-specific issues exist.
Description
CITATION: Seddon, J. A. & Schaaf, H. S. 2016. Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia, 8:20, doi:10.1186/s41479-016-0019-5.
The original publication is available at https://pneumonia.biomedcentral.com
The original publication is available at https://pneumonia.biomedcentral.com
Keywords
Tuberculosis in children -- Treatment
Citation
Seddon, J. A. & Schaaf, H. S. 2016. Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia, 8:20, doi:10.1186/s41479-016-0019-5